The protein stability and transcriptional activity of p63α are regulated by SUMO-1 conjugation

Cell Cycle

Volumn 4, Issue 1, 2005, Pages 183-190

  Ghioni, Pamela ^a   D'Alessandra, Yuri ^a   Mansueto, Gelsomina ^b   Jaffray, Ellis ^c   Hay, Ronald T ^c   La Mantia, Girolama ^b   Guerrini, Luisa ^a,d  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF ST ANDREWS   (United Kingdom)

^d Department of Biomolecular and Biotechnological Sciences ^*  (Italy)

Author keywords

Development; p63; SUMO 1

Indexed keywords

ARGININE; PROTEASOME; PROTEIN P63; SUMO 1 PROTEIN; UBIQUITIN;

ARTICLE; CHEMICAL REACTION; CONJUGATION; GENE MUTATION; HUMAN; HUMAN CELL; NUCLEAR LOCALIZATION SIGNAL; PROTEIN DOMAIN; PROTEIN LOCALIZATION; PROTEIN PROCESSING; PROTEIN STABILITY; SUMOYLATION; TRANSCRIPTION REGULATION; WILD TYPE;

EID: 17644407601     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.4.1.1359     Document Type: Article

References (48)

1. Irwin MS, Kaelin WG. p53 family update: p73 and p63 develop their own identities. Cell Growth Differ 2001; 12:337-49.
2. Lohrum MAE, Vousden KH. Regulation and function of the p53-related proteins: Same family, different rules. Trends Cell Biol 2000; 10:197-202.
3. Melino G, Lu X, Gasco M, Crook T, Knight RA. Functional regulation of p73 and p63: Development and cancer. Trends Biochem Sci 2003; 28:663-70.
4. Yang A, Kaghad M, Caput D, McKeon F. On the shoulders of giants: p63, p73 and the rise of p53. Trends Genet 2002; 18:90-5.
5. Yang A, McKeon F. p63 and p73: p53 mimics, menaces and more. Mol Cell Biol 2000; 1:199-207.
6. Blandino G, Dobbelstein M. p73 and p63: Why do we still need them? Cell Cycle 2004; 3:884-5.
7. Kim CA, Bowie JU. SAM domains: Uniform structure, diversity of function. Trends Biochem Sci 2003; 28:625-8.
8. Brunner HG, Hamel BC, Van Bokhoven H. The p63 gene in EEC and other syndromes. J Med Genet 2002; 39:377-81.
9. van Bokhoven H, Brunner HG. Splitting p63. Am J Hum Genet 2002; 71:1-13.
10. Koster MI, Kim S, Mills AA, De Mayo FJ, Roop DR. p63 is the molecular switch for initiation of an epithelial stratification program. Genes Dev 2004; 18:126-31.
11. Liefer KM, Koster MI, Wang XJ, Yang A, McKeon F, Roop DR. Down-regulation of p63 is required for epidermal UV-B-induced apoptosis. Cancer Res 2000; 60:4016-20.
12. Maisse C, Guerrieri P, Melino G. p73 and p63 protein stability: The way to regulate function? Biochem Pharmacol 2003; 66:1555-6.
13. Katoh I, Aisaki K, Kurata S, Ikawa S, Ikawa Y. p51A (TAp63γ), a p53 homolog, accumulates in response to DNA damage for cell regulation. Oncogene 2000; 19:3126-30.
14. Fomenkov A, Zangen R, Huang YP, Osada M, Guo Z, Fomenkov T, et al. RACK1 and stratifin target ΔNp63α for a proteasome degradation in head and neck squamous cell carcinoma. Cell Cycle 2004; 3:1285-95.
15. May P, May E. Twenty years of p53 research: Structural and functional aspects of the p53 protein. Oncogene 1999; 18:7621-36.
16. Caspari T. Checkpoints: How to activate p53. Curr Biol 2000; 10:R315-7.
17. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997; 387:296-9.
18. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997; 387:299-303.
19. Calabrò V, Mansueto G, Parisi T, Vivo M, Calogero R, La Mantia G. The human MDM2 oncoprotein increases the transcriptional activity and the protein level of thep53- homologue p63. J Biol Chem 2002; 277:2674-81.
20. Calabrò V, Mansueto G, Santoro R, Gentilella A, Pollice A, Ghioni P, Guerrini L, La Mantia G. Inhibition of p63 trascriptional activity by p14ARF: A functional and physical link between human ARF tumor suppressor and a member of the p53 family. Mol Cell Biol 2004; 19:8529-40.
21. Lemon B, Tjian R. Orchestrated response: A symphony of transcription factors for gene control. Genes Dev 2000; 14:2551-69.
22. Freiman RN, Tjian R. Regulating the regulators: Lysine modifications make their mark. Cell 2003; 112:11-7.
23. Wilkinson CR. Ubiquitin-like proteins: Meet the family. Semin Cell Dev Biol 2004; 15:199-200.
24. Lapenta V, Chiurazzi P, van der Spek P, Pizzuti A, Hanaoka F, Brahe C. SMT3A, a human homologue of the S. cerevisiae SMT3 gene, maps to chromosome 21 qter and defines a novel gene family. Genomics 1997; 40:362-6.
25. Saitoh H, Hinchey J. Functional heterogeneity of small ubiquitin-related protein modifiers SUMO-1 versus SUMO-2/3. J Biol Chem 2000; 275:6252-8.
26. Vertegaal AC, Ogg SC, Jaffray E, Rodriguez MS, Hay RT, Andersen JS, Mann M, Lamond AI. A proteomic study of SUMO-2 target proteins. J Biol Chem 2004; 279:33791-8.
27. Watts FZ. SUMO modification of proteins other than transcription factors. Semin Cell Dev Biol 2004; 15:211-20.
28. Bernardi R, Scaglioni PP, Bergmann S, Horn HF, Vousden KH, Pandolfi PP. PML regulates p53 stability by sequestering Mdm2 to the nucleolus. Nat Cell Biol 2004; 6:665-72.
29. Kamitani T, Kito K, Nguyen HP, Wada H, Fukuda-Kamitani T, Yeh ET. Identification of three major sentrinization sites in PML. J Biol Chem 1998; 273:26675-8.
30. Desterro JM, Rodriguez MS, Hay RT. SUMO-1 modification of IκBα inhibits NF-κB activation. Mol Cell 1998; 2:233-9.
31. Zhang H, Smolen GA, Palmer R, Christoforou A, van den Heuvel S, Haber DA. SUMO modification is required for in vivo Hox gene regulation by the Caenorhabditis elegans Polycomb group protein SOP-2. Nat Genet 2004; 36:507-11.
32. Gill G. Post-translational modification by the small ubiquitin-related modifier SUMO has big effects on transcription factor activity. Curr Opin Genet Dev 2003; 13:108-11.
33. Girdwood DW, Tatham MH, Hay RT. SUMO and transcriptional regulation. Semin Cell Dev Biol 2004; 15:201-10.
34. Minty A, Dumont X, Kaghad M, Caput D. Covalent modification of p73α by SUMO-1. Two-hybrid screening with p73 identifies novel SUMO-1-interacting proteins and a SUMO-1 interaction motif. J Biol Chem 2000; 275:36316-23.
35. Ghioni P, Bolognese F, Duijf PH, Van Bokhoven H, Mantovani R, Guerrini L. Complex transcriptional effects of p63 isoforms: Identification of novel activation and repression domains. Mol Cell Biol 2002; 22:8659-68.
36. Girdwood D, Bumpass D, Vaughan OA, Thain A, Anderson LA, Snowden AW, et al. P300 transcriptional repression is mediated by SUMO modification. Mol Cell 2003; 11:1043-54.
37. Rodriguez MS, Desterro JM, Lain S, Midgley CA, Lane DR Hay RT. SUMO-1 modification activates the transcriptional response of p53. EMBO J 1999; 22:6455-61.
38. Pellegrini G, Dellambra E, Golisano O, Martinelli E, Fantozzi I, Bondanza S, et al. p63 identifies keratinocyte stem cells. Proc Natl Acad Sci USA 2001; 98:3156-61.
39. Thurfjell N, Coates PJ, Uusitalo T, Mahani D, Dabelsteen E, Dahlqvist A, et al. Complex p63 mRNA isoform expression patterns in squamous cell carcinoma of the head and neck. Int J Oncol 2004; 25:27-35.
40. Rodriguez MS, Dargemont C, Hay RT. SUMO-1 conjugation in vivo requires both a consensus modification motif and nuclear targeting. J Biol Chem 2001; 276:12654-9.
41. Serber Z, Lai HC, Yang A, Ou HD, Sigal MS, Kelly AE, Darimont BD, Duijf PH, Van Bokhoven H, McKeon F, Dotsch V. A C-terminal inhibitory domain controls the activity of p63 by an intramolecular mechanism. Mol Cell Biol 2002; 22:8601-11.
42. Pichler A, Melchior F. Ubiquitin-related modifier SUMO1 and nucleocytoplasmic transport. Traffic 2002; 3:381-7.
43. Verger A, Perdomo J, Crossley M. Modification with SUMO. A role in transcriptional regulation. EMBO Rep 2003; 4:137-42.
44. Morriss-Kay GM, Sokolova N. Embryonic development and pattern formation. FASEB J 1996; 10:961-8.
45. Van Dyck F, Delvaux EL, Van De Ven WJ, Chavez MV. Repression of the transactivating capacity of the oncoprotein PLAG1 by SUMOylation. J Biol Chem 2004.
46. Le Drean Y, Mincheneau N, Le Goff P, Michel D. Potentiation of glucocorticoid receptor transcriptional activity by sumoylation. Endocrinology 2002; 143:3482-9.
47. Floyd ZE, Stephens JM. Control of peroxisome proliferator-activated receptor g2 stability and activity by SUMOylation. Obes Res 2004; 12:921-8.
48. Huang YP, Wu G, Guo Z, Osada M, Fomenkov T, Park HL, Trink B, Sidransky D, Fomenkov A, Ratovitski EA. Altered sumoylation of p63α contributes to the split-hand/foot malformation phenotype. Cell Cycle 2004; In press.